Join MitoAction and Dr. Jan Smeitink, CEO of Khondrion for our our March Expert Series presentation. MELAS spectrum (m.3243A>G) disorders belong to the most frequently encountered group of primary mitochondrial diseases with an unmet medical need for treatment development. Following an introduction of the clinical disease spectrum Dr. Smeitink will discuss the development and state-of-art of Khondrion’s lead product sonlicromanol.
Is Exercise a New Year’s Resolution for People Affected by Mitochondrial Diseases? Learn about how you can most effectively incorporate exercise into your daily...
Join in to listen to RN, Julie Gortze.
MITO Meeting: MONTHLY INTERNATIONAL TELECONFERENCE OUTREACH Join us with Dr. Katherine Sims from Massachusetts General Hospital as we take a closer look at understanding...